International Stem Cell Corp. Stock Price - ISCO

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
International Stem Cell Corp. (QB) ISCO OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.10 -16.67% 0.50 0.50 0.3601 0.39 0.60 16:00:01
Bid Price Ask Price Spread Spread % News
0.3512 0.50 0.1488 29.76% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7 5,465 $ 0.448493 $ 2,451 2,872 0.352 - 1.90
Last Trade Time Type Quantity Stock Price Currency
15:40:15 889 $ 0.50 USD

International Stem Cell Corp. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.77M 7.53M $ -2.13M - - 2.19M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
56.11k $ - 0.00% - -

more financials information »

International Stem Cell Corp. News

Loading Messages....

Latest ISCO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ISCO Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.410.60.3520.46405k0.0921.95%
1 Month0.60.660.3520.51384k-0.1-16.67%
3 Months0.840.920.3520.61113k-0.34-40.48%
6 Months1.31.350.3520.87274k-0.8-61.54%
1 Year1.621.90.3521.23305k-1.12-69.14%
3 Years1.8362.50.3521.43386k-1.336-72.77%
5 Years0.0716.950.04040.1851110k0.429604.23%

International Stem Cell Corp. Description

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care (

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.